| Primary |
| Drug Use For Unknown Indication |
20.5% |
| Thrombosis Prophylaxis |
16.7% |
| Deep Vein Thrombosis |
9.7% |
| Pulmonary Embolism |
8.9% |
| Product Used For Unknown Indication |
6.8% |
| Prophylaxis |
6.5% |
| Atrial Fibrillation |
6.4% |
| Pain |
4.4% |
| Hypertension |
4.1% |
| Thrombosis |
3.6% |
| Anticoagulant Therapy |
2.3% |
| Depression |
1.7% |
| Acute Coronary Syndrome |
1.6% |
| Antiphospholipid Syndrome |
1.0% |
| Anaesthesia |
1.0% |
| Anxiety |
1.0% |
| Epilepsy |
1.0% |
| Erysipelas |
1.0% |
| Induction Of Anaesthesia |
1.0% |
| Hypothyroidism |
0.9% |
|
| Death |
13.3% |
| Thrombocytopenia |
10.1% |
| Pulmonary Embolism |
9.2% |
| Injury Associated With Device |
6.4% |
| Thrombosis |
5.9% |
| Retroperitoneal Haemorrhage |
5.6% |
| Renal Failure Acute |
5.2% |
| Drug Exposure During Pregnancy |
5.1% |
| Vomiting |
5.1% |
| Heparin-induced Thrombocytopenia |
4.3% |
| White Blood Cell Count Increased |
3.7% |
| Neutropenia |
3.6% |
| White Blood Cell Count Abnormal |
3.3% |
| Product Quality Issue |
3.0% |
| Thrombocythaemia |
3.0% |
| Medication Error |
2.9% |
| Haematoma |
2.7% |
| Haemorrhage |
2.6% |
| Platelet Count Decreased |
2.6% |
| Renal Failure |
2.4% |
|
| Secondary |
| Product Used For Unknown Indication |
31.8% |
| Drug Use For Unknown Indication |
24.6% |
| Thrombosis Prophylaxis |
6.7% |
| Deep Vein Thrombosis |
6.6% |
| Pulmonary Embolism |
5.4% |
| Atrial Fibrillation |
3.7% |
| Hypertension |
3.0% |
| Prophylaxis |
3.0% |
| Pain |
2.6% |
| Anticoagulant Therapy |
2.3% |
| Thrombosis |
2.2% |
| Myocardial Infarction |
1.4% |
| Depression |
1.3% |
| Acute Coronary Syndrome |
0.9% |
| Premedication |
0.8% |
| Foetal Exposure During Pregnancy |
0.8% |
| Antiphospholipid Syndrome |
0.8% |
| Nausea |
0.7% |
| Colitis |
0.7% |
| Erysipelas |
0.7% |
|
| Thrombocytopenia |
15.0% |
| White Blood Cell Count Increased |
13.1% |
| Renal Failure Acute |
8.4% |
| Pulmonary Embolism |
6.8% |
| Thrombosis |
6.4% |
| Vomiting |
6.3% |
| Haematoma |
5.2% |
| Retroperitoneal Haemorrhage |
4.3% |
| Wound Secretion |
4.0% |
| Neutropenia |
3.3% |
| Toxic Skin Eruption |
3.3% |
| Cytolytic Hepatitis |
3.0% |
| Nausea |
2.9% |
| Pyrexia |
2.9% |
| Subdural Haematoma |
2.9% |
| Drug Ineffective |
2.6% |
| Haemorrhage |
2.5% |
| Deep Vein Thrombosis |
2.4% |
| Muscle Haemorrhage |
2.3% |
| International Normalised Ratio Increased |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
37.3% |
| Drug Use For Unknown Indication |
25.3% |
| Pain |
5.5% |
| Multiple Myeloma |
4.8% |
| Hypertension |
3.0% |
| Prophylaxis |
2.7% |
| Thrombosis Prophylaxis |
2.5% |
| Diffuse Large B-cell Lymphoma |
2.2% |
| Nausea |
2.0% |
| Non-small Cell Lung Cancer |
1.8% |
| Depression |
1.6% |
| Deep Vein Thrombosis |
1.6% |
| Anxiety |
1.4% |
| Anticoagulant Therapy |
1.3% |
| Constipation |
1.3% |
| Pulmonary Embolism |
1.2% |
| Atrial Fibrillation |
1.2% |
| Rheumatoid Arthritis |
1.1% |
| Prostate Cancer |
1.1% |
| Breast Cancer |
1.0% |
|
| Vomiting |
13.2% |
| Pulmonary Embolism |
9.4% |
| Weight Decreased |
8.3% |
| Thrombocytopenia |
7.5% |
| Death |
5.5% |
| Pain |
4.9% |
| Urinary Tract Infection |
4.9% |
| Renal Failure Acute |
4.6% |
| Pneumonia |
4.4% |
| Pyrexia |
4.3% |
| Sepsis |
4.1% |
| Renal Failure |
3.9% |
| Weight Increased |
3.9% |
| Thrombosis |
3.8% |
| Deep Vein Thrombosis |
3.5% |
| White Blood Cell Count Decreased |
3.1% |
| White Blood Cell Count Increased |
3.1% |
| Neutropenia |
3.0% |
| Respiratory Failure |
2.5% |
| Dyspnoea |
2.2% |
|
| Interacting |
| Product Used For Unknown Indication |
35.8% |
| Acute Coronary Syndrome |
8.0% |
| Drug Use For Unknown Indication |
6.8% |
| Atrial Fibrillation |
6.3% |
| Hypertension |
6.3% |
| Deep Vein Thrombosis |
4.5% |
| Cardiac Failure |
4.0% |
| Iliac Artery Stenosis |
3.4% |
| Parkinson's Disease |
3.4% |
| Acute Lymphocytic Leukaemia |
2.8% |
| Arrhythmia |
2.8% |
| Cerebrovascular Accident Prophylaxis |
2.8% |
| Depression |
1.7% |
| Diabetes Mellitus |
1.7% |
| Pain |
1.7% |
| Prophylaxis |
1.7% |
| Sciatica |
1.7% |
| Thrombosis |
1.7% |
| Thrombosis Prophylaxis |
1.7% |
| Coronary Arterial Stent Insertion |
1.1% |
|
| Haematoma |
15.8% |
| Hypoaesthesia |
10.5% |
| International Normalised Ratio Increased |
7.9% |
| Drug Interaction |
5.3% |
| Labile Blood Pressure |
5.3% |
| Melaena |
5.3% |
| Overdose |
5.3% |
| Pallor |
5.3% |
| Puncture Site Haemorrhage |
5.3% |
| Throat Irritation |
5.3% |
| Thrombosis |
5.3% |
| Anaemia |
2.6% |
| Dyspnoea |
2.6% |
| Epistaxis |
2.6% |
| Gingival Bleeding |
2.6% |
| Haemoglobin Decreased |
2.6% |
| Haemorrhagic Stroke |
2.6% |
| Hemiparesis |
2.6% |
| Muscle Haemorrhage |
2.6% |
| Oedema Peripheral |
2.6% |
|
